Abstract:Summary Objectives The primary objective of this study is to investigate if false vocal folds (FVF) or simultaneous FVF with thyroarytenoid (FVF + TA) Botox® injections achieve comparable treatment effects to standard TA injections. This study also aims to determine how patient-reported outcomes contribute to the transition to, and continuation of, FVF or FVF + TA injections. Methods Retrospective chart review was performed for all patients receiving Botox® for adductor spasmodic dysphonia at a laryngology practice between 2005 and 2018. Twenty out of 103 patients met the study's inclusion criteria. All subjects began standard treatment with TA injections. Based on response to injection, patients either continued to receive TA injections (group TA; n = 7), switched to FVF injections (group FVF; n = 7), or switched to FVF + TA injections (group FVF + TA; n = 6). A comparison of group means before and after initiation of FVF ± TA injections was performed between groups FVF and FVF + TA to group TA for the injection dosage, the duration of injection cycles, the patient-reported duration of best voice, and the presence and duration of breathiness and choking. Within-group observations were also compared before and after FVF ± TA injections. Results There were no significant findings for the variables between group FVF and group TA before FVF injections. The duration of injection cycles was significantly shorter for group FVF than group TA after FVF injections (95% CI: − 66.05, − 0.34; P = 0.05). However, duration of best voice quality, breathiness, and choking were similar ( P > 0.05) for group FVF to group TA after FVF injections. Group FVF + TA had a significantly shorter duration of injection cycles (95% CI: − 66.97, − 3.22; P = 0.03), best voice (95% CI: − 0.76, − 0.03; P = 0.04), and choking (95% CI: − 2.68, 0.02; P = 0.05) than group TA before FVF + TA injections. Group FVF + TA displayed a similar duration ( P > 0.05) of injection cycles, best voice quality, breathiness, and choking to group TA after FVF + TA injections. Within-group, increased duration of injection cycles and best voice were observed after FVF ± TA injections for both group FVF and FVF + TA. Acute adverse events were variable within groups after FVF ± TA injections. Conclusion This study compared outcomes of FVF or FVF + TA injections to successive TA injections among patients. FVF injections displayed similar duration of best voice quality, breathiness, and choking to TA injections. FVF + TA injections achieved similar duration of injection cycles, best voice quality, breathiness, and choking to TA injections. This study demonstrates that patients guided by a reduced duration of adverse events, while tolerating a shorter injection cycle, may benefit from initiation and continuation of FVF injections. Patients guided by increased duration of injection cycle and best voice, while tolerating the duration of adverse events, may benefit from initiation and continuation of FVF + TA injections.

Comparison of Botulinum Toxin Injections and Type 2 Thyroplasty for Adductor Spasmodic Dysphonia

Botulinum Toxin Therapy for Spasmodic Dysphonia in Japan: The History and an Update

Validity of intraoperative voice monitoring undergoing type 2 thyroplasty with titanium bridges for adductor spasmodic dysphonia

Transnasal Endoscopic Injection of Botulinum Toxin in Patients with Adductor Spasmodic Dysphonia

Durability of Titanium Implants Following Type II Thyroplasty for Adductor Type Spasmodic Dysphonia

Patient-Reported Outcomes after False Vocal Folds Injections for Adductor Spasmodic Dysphonia

Comparison of the efficacy and adverse effects of unilateral or bilateral botulinum toxin injections for adductor spasmodic dysphonia: a systematic review and meta-analysis

[Patterns of Spasmodic Dysphonia and Botulinum Toxin Injections].

Tremor Makes a Difference: A Comparative Study of the Demographics and Treatment Outcomes in Patients With Adductor Spasmodic Dysphonia With or Without Vocal Tremor

Bilateral Thyroarytenoid Denervation: A New Treatment for Laryngeal Hyperadduction Disorders Studied in the Canine

Clinical Effectiveness of Ultrasound Guided Subacromial-Subdeltoid Bursa Injection of Botulinum Toxin Type A in Hemiplegic Shoulder Pain A Retrospective Cohort Study

Quality of Life and Voice Changes After a Single Injection in Patients With ADSD Over Time

Repeatedly successful closure of the larynx for the treatment of chronic aspiration with the use of botulinum toxin A

Voice Therapy Outcome Post Transoral Thyroarytenoid Myoneurectomy in Adductor Spasmodic Dysphonia: A Case Series

Voice outcome in medialisation thyroplasty with and without arytenoid adduction: a prospective comparison using intraoperative voice measurements

Significance of age and sex in botulinum neurotoxin dosing for adductor spasmodic dysphonia

Botulinum Toxin injection in Bilateral Vocal Fold Immobility

Supraglottic Botulinum Toxin Improves Symptoms in Patients with Laryngeal Sensory Dysfunction Manifesting as Abnormal Throat Sensation and/or Chronic Refractory Cough

Airway and Voice Outcomes After Thyroarytenoid Myomectomy for Bilateral Vocal Fold Immobility

Effects of an 11-week vibro-tactile stimulation treatment on voice symptoms in laryngeal dystonia

Turbinate Injection of Botulinum Toxin in the Treatment of the Chronic Rhinitis